Tandem Diabetes has announced that the t:slim X2 insulin pump, featuring Control-IQ+ automated insulin delivery (AID) technology, is now available with Abbott’s FreeStyle Libre 3 Plus ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a global insulin delivery and diabetes technology company, announced that the ...

Abbott’s latest innovation, the FreeStyle Libre® 2 Plus sensor, is available for the first time for t:slim X2™ insulin pump users in the U.S. Tandem’s Control-IQ™ hybrid closed-loop technology now ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM) and Dexcom, Inc. (Nasdaq: DXCM), today announced that the Tandem Mobi insulin pump with Control-IQ technology is now fully ...

Tandem Diabetes Care (Nasdaq:TNDM) today announced the rollout of its latest automated insulin delivery system integration.

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (TNDM), a leading insulin delivery and diabetes technology company, today announced that its t:slim X2 insulin pump with Control-IQ automated ...

Tandem Diabetes Care's t:slim X2 Insulin Pump Automated Insulin Delivery System is now the first to incorporate the Abbott FreeStyle Libre 2 Plus Sensor for users in the United States. The FreeStyle ...

The next big thing on Tandem Diabetes Care’s technology slate is actually a very small thing. The Mobi insulin pump—which is the company's smallest device to date and, it claims, the smallest ...

The United States Insulin Pump Market is projected to grow from US$ 1.55 billion in 2024 to US$ 2.58 billion in 2033, with a ...

After a successful limited rollout of its newest insulin pump in the U.S., Tandem Diabetes Care is picking up the pace. The Mobi pump will now begin a widespread national launch, with Tandem already ...

Tandem Diabetes Care's iOS app and insulin pump has made more than 100 people need medical care, resulting in two hospitalizations this year so far. Tandem Diabetes recalled 85,863 devices in May and ...

Tandem Diabetes Care, Inc. TNDM recently announced the publication of favorable study outcomes from the Protocol 5 study (DCLP5) of the International Diabetes Closed Loop (iDCL) trial in the New ...